Federal contract award
75N91020P00862
NATIONAL CANCER CENTER:1222668 [20-035188] GENOTYPING FOR EXPANDED FEMALE LUNG CANCER CONSORTIUM IN ASIA: JAPAN (CAS: 10414)
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 622310 — Specialty (except Psychiatric and Substance Abuse) Hospitals |
| PSC | Q301 — Reference Laboratory Testing |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $0 |
| Current contract value | $0 |
| Potential contract value / ceiling | $0 |
| Start date | Aug 31, 2020 |
| Current end date | Sep 29, 2021 |
| Potential end date | Sep 29, 2021 |
| Latest award activity | May 27, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 27, 2025 | P00001 | $-24.0K | TO DE-OBLIGATE FUNDS FROM FY2020 EXPIRING LINES FOLLOWING NIH OALM COMMUNICATION 25-06 (20241105), REPLACED WITH 75N91025P0039 DUE TO ISSUES WITH SAM REGISTRATION. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.